These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36293001)

  • 1. A Metabolism-Related Gene Prognostic Index for Prediction of Response to Immunotherapy in Lung Adenocarcinoma.
    Tang B; Hu L; Jiang T; Li Y; Xu H; Zhou H; Lan M; Xu K; Yin J; Su C; Zhou C; Xu C
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma.
    Chen X; Zhang T; He YQ; Miao TW; Yin J; Ding Q; Yang M; Chen FY; Zeng HP; Liu J; Zhu Q
    BMC Pulm Med; 2024 May; 24(1):248. PubMed ID: 38764064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid metabolism-related gene prognostic index (LMRGPI) reveals distinct prognosis and treatment patterns for patients with early-stage pulmonary adenocarcinoma.
    Jiang A; Chen X; Zheng H; Liu N; Ding Q; Li Y; Fan C; Fu X; Liang X; Tian T; Ruan Z; Yao Y
    Int J Med Sci; 2022; 19(4):711-728. PubMed ID: 35582412
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
    Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma.
    Chen H; Lin R; Lin W; Chen Q; Ye D; Li J; Feng J; Cheng W; Zhang M; Qi Y
    Sci Rep; 2022 May; 12(1):8230. PubMed ID: 35581376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma.
    Zhang W; Shang X; Liu N; Ma X; Yang R; Xia H; Zhang Y; Zheng Q; Wang X; Liu Y
    BMC Pulm Med; 2022 Dec; 22(1):483. PubMed ID: 36539782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating subtypes of lung adenocarcinoma by oxidative stress and immunotherapy related genes.
    Duan G; Huang C; Zhao J; Zhang Y; Zhao W; Dai H
    Sci Rep; 2023 Nov; 13(1):20930. PubMed ID: 38017020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.
    Yi M; Li A; Zhou L; Chu Q; Luo S; Wu K
    Cancer Immunol Immunother; 2021 Jun; 70(6):1705-1719. PubMed ID: 33386920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of prognostic model based on immunotherapy related genes in lung adenocarcinoma.
    Zhang P; Wang W; Liu L; Li H; Sha X; Wang S; Huang Z; Zhou Y; Shi J
    Sci Rep; 2022 Dec; 12(1):22077. PubMed ID: 36543847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment.
    Huang D; Tang E; Zhang T; Xu G
    Front Immunol; 2022; 13():916284. PubMed ID: 35860256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redox
    Wei XW; Lu C; Zhang YC; Fan X; Xu CR; Chen ZH; Wang F; Yang XR; Deng JY; Yang MY; Gou Q; Mei SQ; Luo WC; Zhong RW; Zhong WZ; Yang JJ; Zhang XC; Tu HY; Wu YL; Zhou Q
    Oncoimmunology; 2024; 13(1):2340154. PubMed ID: 38601319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonnegative matrix factorization-based bioinformatics analysis reveals that TPX2 and SELENBP1 are two predictors of the inner sub-consensuses of lung adenocarcinoma.
    Wang H; Wang X; Xu L; Cao H; Zhang J
    Cancer Med; 2021 Dec; 10(24):9058-9077. PubMed ID: 34734491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma.
    Feng W; He Z; Shi L; Zhu Z; Ma H
    Biochem Genet; 2023 Oct; 61(5):1937-1966. PubMed ID: 36892747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the immune cell infiltration landscape in lung adenocarcinoma.
    Ou HB; Wei Y; Liu Y; Zhou FX; Zhou YF
    Arch Biochem Biophys; 2022 May; 721():109168. PubMed ID: 35346643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic model of lung adenocarcinoma constructed by the CENPA complex genes is closely related to immune infiltration.
    Zhou H; Bian T; Qian L; Zhao C; Zhang W; Zheng M; Zhou H; Liu L; Sun H; Li X; Zhang J; Liu Y
    Pathol Res Pract; 2021 Dec; 228():153680. PubMed ID: 34798483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.
    Wu J; Li L; Zhang H; Zhao Y; Zhang H; Wu S; Xu B
    Oncogene; 2021 Jul; 40(26):4413-4424. PubMed ID: 34108619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.